logo
  

Avon Products Says Didn't Receive Offer From PTG Capital Partners

Avon Products Inc. (AVP) said that it has not received any offer or other communication from PTG Capital Partners and has not been able to confirm that such an entity exists.

Earlier, PTG Capital Partners disclosed in a regulatory filing that it has submitted an offer to the board of directors of Avon Products proposing to acquire all of the Company's outstanding stock, and outstanding options to acquire such shares, in a recommended cash tender offer at a price per share of US$18.75.

PTG Partners said it is committed to working quickly to complete due diligence and execute a definitive agreement, and expects to be able to complete such an agreement within 10 days from the beginning of the due diligence period.

PTG Partners requested that the Company respond promptly, to the Proposed Offer.

Meanwhile, the U.S. Securities and Exchange Commission enforcement division is reviewing the legitimacy of a takeover offer of Avon Products Inc. that sent its shares soaring Thursday, Bloomberg reported citing a person with knowledge of the matter said. The SEC filing included errors, including naming a law firm that doesn't exist.

AVP closed Thursday's trading at $7.07 up $0.40 or 6.00%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT